CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...